Generic Semaglutide India Sales Decline As Volume Slows

Domestic pharmaceutical companies in India are scaling back financial projections for generic semaglutide formulations as early market enthusiasm transitions to sluggish demand. Initial sales targets face significant reductions due to low physician prescription rates, high patient discontinuation, and aggressive pricing strategies implemented by multinational innovators.

Mumbai: A sudden deceleration in market momentum has compromised the early commercial optimism surrounding generic weight-loss treatments within the Indian pharmaceutical landscape.

Domestic manufacturers entered the generic semaglutide segment with aggressive first-year commercial targets but are now quietly reducing their revenue objectives. Industry insiders attribute this strategic recalibration to stagnant prescription volumes and poor long-term patient adherence.

Multiple pharmaceutical operations that originally projected annual revenues between ₹100 crore and ₹150 crore from their GLP-1 lines are now bracing for a 25-30% contraction in sales forecasts. This adjustment stems from conservative prescribing habits among doctors, fierce competition from original brand manufacturers, high drop-off rates, and complications related to delivery devices.

Also Read: GLP-1 rush: Pharma, food firms eye tie-ups for weight-loss boom

Supply chain channels currently hold a substantial surplus, with stockists and wholesale distributors carrying an excess inventory exceeding ₹100 crore.

Corporate leadership teams noted that their primary operational challenge is the sudden flattening of prescription numbers following an initial introductory spike. This pattern deviates from the typical trajectory of a new therapeutic segment, where medical uptake generally accelerates consistently over the opening multi-month period.

GLP-1 drugs slimming down

Medical analysts emphasized that unexpected price reductions by the innovator firm Novo Nordisk fundamentally disrupted the projections of generic manufacturers.

Indian corporations anticipated positioning their generic offerings at elevated price tiers, but the resulting price competition compressed profit margins far ahead of schedule and altered the commercial viability of the products, according to Mumbai-based diabetologist Rajiv Kovil.

Though priced below the branded innovations of Novo Nordisk, the generic alternatives require a monthly expenditure of Rs 2,000 to Rs 4,000, presenting a steep financial barrier for average Indian consumers.

India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales

The plateauing of prescription acquisition indicates that patient retention rates are tracking well below internal corporate models, Kovil added.

The changing market environment has prompted pharmaceutical firms preparing for secondary market entries to adopt a cautious stance. Executives revealed that next-phase brand deployment schedules are being pushed back by several months to let the initial volatility settle, with a potential demand resurgence delayed until the third or fourth fiscal quarter of 2026.

Future Outlook

The immediate future of the anti-obesity therapeutic segment in India depends heavily on structural affordability and device simplification. As generic manufacturers reassess their manufacturing costs and supply chain margins against multinational price adjustments, the market is expected to undergo a consolidation phase. Industry analysts anticipate that a volume recovery will require targeted medical education campaigns to improve patient adherence and reduce discontinuation rates before late 2026.

FAQs

Why are Indian pharmaceutical companies lowering sales targets for weight-loss drugs?

Domestic manufacturers are reducing their revenue goals by 25-30% due to slower-than-expected prescription growth, high patient discontinuation rates, and intense price competition from innovator brands.

How much excess inventory is currently held by stockists in India?

Wholesale distributors and market stockists are currently holding an inventory backlog valued at over ₹100 crore due to a sudden drop in market demand after the initial launch surge.

What is the average monthly cost of generic semaglutide in India?

A monthly course of generic semaglutide ranges between Rs 2,000 and Rs 4,000, which remains a significant financial constraint for the broader consumer base in the country.

When is the second wave of generic GLP-1 drug launches expected?

Pharmaceutical executives indicate that upcoming product launches have been deferred and may not see a market rollout until the third or fourth quarter of the current fiscal year.